

SHOPPERS DRUG MART CORPORATION
2011 FIRST QUARTER REPORT TO SHAREHOLDERS

1	TABLE OF CONTENTS
2	MANAGEMENT'S DISCUSSION AND ANALYSIS
2	FORWARD-LOOKING INFORMATION AND STATEMENTS
3	OVERVIEW
5	OVERALL FINANCIAL PERFORMANCE
5	Key Operating, Investing and Financial Metrics
6	Results of Operations
9	Capitalization and Financial Position
11	Liquidity and Capital Resources
13	NEW ACCOUNTING PRONOUNCEMENTS
13	Transition to International Financial Reporting Standards
13	Future Accounting Standards
14	SELECTED QUARTERLY INFORMATION
15	RISKS AND RISK MANAGEMENT
17	RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS
19	INTERNAL CONTROL OVER FINANCIAL REPORTING
19	NON-IFRS FINANCIAL MEASURES
20	CONSOLIDATED FINANCIAL STATEMENTS
20	CONSOLIDATED STATEMENTS OF EARNINGS
21	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
22	CONSOLIDATED BALANCE SHEETS
23	CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
24	CONSOLIDATED STATEMENTS OF CASH FLOWS
25	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SHOPPERS DRUG MART CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS

As at April 25, 2011

The following is a discussion of the consolidated financial condition and results of operations of Shoppers Drug Mart Corporation (the "Company") for the periods indicated and of certain factors that the Company believes may affect its prospective financial condition, cash flows and results of operations. This discussion and analysis should be read in conjunction with the unaudited consolidated financial statements of the Company and the notes thereto for the 12 week period ended March 26, 2011. The Company's unaudited interim period financial statements and the notes thereto have been prepared in accordance with International Financial Reporting Standards ("IFRS") and are reported in Canadian dollars. (See "Transition to International Financial Reporting Standards" under "New Accounting Pronouncements" in this Management's Discussion and Analysis.) These financial statements do not contain all disclosures required by IFRS for annual financial statements and, accordingly, should also be read in conjunction with the most recently prepared annual consolidated financial statements for the 52 week period ended January 1, 2011, which have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP").

FORWARD-LOOKING INFORMATION AND STATEMENTS

This document contains forward-looking information and statements which constitute "forward-looking information" under Canadian securities law and which may be material regarding, among other things, the Company's beliefs, plans, objectives, estimates, intentions and expectations. Forward-looking information and statements are typically identified by words such as "anticipate", "believe", "expect", "estimate", "forecast", "goal", "intend", "plan", "will", "may", "should", "could" and similar expressions. Specific forward-looking information in this document includes, but is not limited to, statements with respect to the Company's future operating and financial results, its capital expenditure plans, its dividend and shareholder distribution policies and the ability to execute on its future operating, investing and financing strategies.

The forward-looking information and statements contained herein are based on certain factors and assumptions, certain of which appear proximate to the applicable forward-looking information and statements contained herein. Inherent in the forward-looking information and statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to control or predict, which give rise to the possibility that the Company's predictions, forecasts, expectations or conclusions will not prove to be accurate, that its assumptions may not be correct and that the Company's plans, objectives and statements will not be achieved. Actual results or developments may differ materially from those contemplated by the forward-looking information and statements.

The material risk factors that could cause actual results to differ materially from the forward-looking information and statements contained herein include, without limitation: the risk of adverse changes to laws and regulations relating to prescription drugs and their sale, including pharmacy reimbursement programs and the availability of manufacturer allowances, or changes to such laws and regulations that increase compliance costs; the risk that the Company will be unable to implement successful strategies to manage the impact of the regulations enacted in 2010 in the Province of Ontario to amend the Ontario drug system, along with the impact of the Pharmacy Services Agreement that came into effect in 2010 in the Province of British Columbia, as well as the impact of the proposed and/or announced drug system reform initiatives in these and other jurisdictions of Canada, principally the provinces of Alberta, Québec, Nova Scotia and Newfoundland and Labrador; the risk of adverse changes in economic and financial conditions in Canada and globally; the risk of increased competition from other retailers; the risk of an inability of the Company to manage growth and maintain its profitability; the risk of exposure to fluctuations in interest rates; the risk of material adverse changes in foreign currency exchange rates; the risk of an inability to attract and retain pharmacists and key employees; the risk of an inability of the Company's information technology systems to support the requirements of the Company's business; the risk of changes to estimated contributions of the Company in respect of its pension plans or post-employment benefit plans which may adversely impact the Company's financial performance; the risk of changes to the relationships of the Company with third-party service

providers; the risk that the Company will not be able to lease or obtain suitable store locations on economically favourable terms; the risk of adverse changes to the Company's results of operations due to seasonal fluctuations; risks associated with alternative arrangements for sourcing generic drug products, including intellectual property and product liability risks; the risk that new, or changes to current, federal and provincial laws, rules and regulations, including environmental and privacy laws, rules and regulations, may adversely impact the Company's business and operations; the risk that violations of law, breaches of Company policies or unethical behaviour may adversely impact the Company's financial performance; property and casualty risks; the risk of injuries at the workplace or health issues; the risk that changes in tax law, or changes in the way that tax law is expected to be interpreted, may adversely impact the Company's business and operations; the risk that new, or changes to existing, accounting pronouncements may adversely impact the Company; the risks associated with the performance of the Associate-owned store network; the risk of material adverse effects arising as a result of litigation; the risk of damage to the reputation of brands promoted by the Company, or to the reputation of any supplier or manufacturer of these brands; and the risk that events or series of events may cause business interruptions.

This is not an exhaustive list of the factors that may affect any of the Company's forward-looking information and statements. Investors and others should carefully consider these and other factors and not place undue reliance on the forward-looking information and statements. Further information regarding these and other factors is included in the Company's public filings with provincial securities regulatory authorities including, without limitation, the sections entitled "Risks and Risk Management" and "Risks Associated with Financial Instruments" in this document and in the Company's Management's Discussion and Analysis for the 52 week period ended January 1, 2011. The forward-looking information and statements contained in this discussion of the consolidated financial condition and results of operations of the Company represent the Company's views only as of the date hereof. Forward-looking information and statements contained in this document about prospective results of operations, financial position or cash flows that are based upon assumptions about future economic conditions and courses of action are presented for the purpose of assisting the Company's shareholders in understanding management's current views regarding those future outcomes and may not be appropriate for other purposes. While the Company anticipates that subsequent events and developments may cause the Company's views to change, the Company does not undertake to update any forward-looking information and statements, except to the extent required by applicable securities laws.

Additional information about the Company, including the Annual Information Form, can be found at www.sedar.com.

OVERVIEW

The Company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). As at March 26, 2011, there were 1,185 Shoppers Drug Mart/Pharmaprix retail drug stores owned and operated by the Company's licensees ("Associates"). An Associate is a pharmacist-owner of a corporation that is licensed to operate a retail drug store at a specific location using the Company's trademarks. The Company's licensed stores are located in prime locations in each province and two territories, making Shoppers Drug Mart/Pharmaprix stores among the most convenient retail outlets in Canada. The Company also licenses or owns 60 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec) and eight luxury beauty destinations operating as Murale™.

The Company has successfully leveraged its leadership position in pharmacy and its convenient store locations to capture a significant share of the market in front store merchandise. Front store merchandise categories include over-the-counter medications, health and beauty aids, cosmetics and fragrances (including prestige brands), everyday household needs and seasonal products. The Company also offers a broad range of high-quality private label products marketed under the trademarks Life Brand®, Quo®, Etival™, Balea®, Everyday Market®, Bio-Life®, Nativa®, Simply Food™ and Easypix®, among others, and value-added services such as the HealthWATCH® program, which offers patient counselling and advice on medications, disease management and health and wellness, and the Shoppers Optimum® program, one of the largest retail loyalty card programs in Canada. In fiscal 2010, the Company recorded consolidated sales of approximately \$10.2 billion.

Under the licensing arrangements with Associates, the Company provides the capital and financial support to enable Associates to operate Shoppers Drug Mart®, Pharmaprix®, Shoppers Simply Pharmacy® and Pharmaprix Simplement Santé® stores without any initial investment. The Company also provides a package of services to facilitate the growth and profitability of each Associate's business. These services include the use of trademarks, operational support, marketing and advertising, purchasing and distribution, information technology and accounting. In return for being provided these and other services, Associates pay fees to the Company. Fixtures, leasehold improvements and equipment are purchased by the Company and leased to Associates over periods ranging from two to 15 years, with title retained by the Company. The Company also provides its Associates with assistance in meeting their working capital and long-term financing requirements through the provision of loans and loan guarantees.

Under the licensing arrangements, the Company receives a substantial share of Associate store profits. The Company's share of Associate store profits is reflective of its investment in, and commitment to, the operations of the Associates' stores.

The Company operates in Québec primarily under the Pharmaprix® and Pharmaprix Simplement Santé® trade names. Under Québec law, profits generated from the prescription area or dispensary may only be earned by a pharmacist or a corporation controlled by a pharmacist. As a result of these restrictions, the licence agreement used for Québec Associates differs from the Associate agreement used in other provinces. Pharmaprix® and Pharmaprix Simplement Santé® stores and their Associates benefit from the same infrastructure and support provided to all other Shoppers Drug Mart® and Shoppers Simply Pharmacy® stores and Associates.

Associate-owned stores comprise the majority of the Company's store network. The Associate-owned stores are separate legal entities and the Company does not have any direct or indirect shareholdings in these Associate-owned stores. The Company consolidates the Associate-owned stores in accordance with International Accounting Standard 27, "Consolidated and Separate Financial Statements" ("IAS 27") based on the concept of control under IAS 27, determined primarily through the licensing arrangements that govern the relationship between the Company and the Associates. However, as the Associate-owned stores remain separate legal entities from the Company, consolidation of these stores has no impact on the underlying risks facing the Company. (See note 3 to the accompanying unaudited consolidated financial statements of the Company.)

The Company also owns and operates 63 Shoppers Home Health Care® stores. These retail stores are engaged in the sale and service of assisted-living devices, medical equipment, home-care products and durable mobility equipment to institutional and retail customers.

In addition to its retail store network, the Company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, and MediSystem Technologies Inc., a provider of pharmaceutical products and services to long-term care facilities in Ontario and Alberta.

The majority of the Company's sales are generated from its retail drug store network and the majority of the Company's assets are used in the operations of these stores. As such, the Company presents one operating segment in its consolidated financial statement disclosures. The revenue generated by Shoppers Drug Mart Specialty Health Network Inc. and by MediSystem Technologies Inc. is included with the prescription sales of the Company's retail drug stores. The revenue generated by the Shoppers Home Health Care® stores and the Murale™ stores is included with the front store sales of the Company's retail drug stores.

OVERALL FINANCIAL PERFORMANCE

Key Operating, Investing and Financial Metrics

The following provides an overview of the Company's operating performance for the 12 week period ended March 26, 2011 compared to the 12 week period ended March 27, 2010⁽¹⁾, as well as certain other metrics with respect to investing activities for the 12 week period ended March 26, 2011 and financial position as at that same date.

- Sales of \$2.347 billion, an increase of 2.7%.
- Comparable store total sales growth of 2.0%.
 - Comparable prescription sales decrease of 0.4%.
 - Comparable front store sales growth of 4.4%.
- Prescription count growth of 3.9%.
 - Comparable store prescription count growth of 3.7%.
- EBITDA⁽²⁾ of \$247 million, an increase of 2.7%.
 - EBITDA margin⁽³⁾ of 10.52%, unchanged compared to the same period of prior year.
- Net earnings of \$118 million or \$0.54 per share (diluted), an increase of 3.3% compared to adjusted net earnings⁽⁴⁾ of \$114 million of \$0.52 per share (diluted) in the first quarter of 2010.
- Capital expenditure program of \$71 million compared to \$99 million in the same period of the prior year.
 - Opened or acquired 18 new drug stores, 11 of which were relocations.
 - Completed four major drug store expansions.
 - 12 drug stores remodelled/converted to smaller prototype formats.
 - Year-over-year increase in retail selling square footage of 4.9%.
- Maintained desired capital structure and financial position.
 - Net debt to equity ratio of 0.29:1 at March 26, 2011 compared to 0.37:1 a year ago.
 - Net debt to total capitalization ratio of 0.22:1 compared to 0.27:1 a year ago.

⁽¹⁾ In preparing its 2010 comparative information, the Company has adjusted amounts reported previously in financial statements prepared in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP"). (See Note 13 to the accompanying unaudited consolidated financial statements of the Company.)

⁽²⁾ Earnings before finance expenses, income taxes and depreciation and amortization. (See reconciliation to the most directly comparable IFRS measure under "Results of Operations" in this Management's Discussion and Analysis and note 8 to the accompanying unaudited consolidated financial statements of the Company.)

⁽³⁾ EBITDA divided by sales.

⁽⁴⁾ Net earnings, excluding the after-tax impact of a gain on disposal of \$12 million (pre-tax) in respect of a sale-leaseback transaction involving certain of the Company's retail properties.

Results of Operations

The following table presents a summary of certain selected consolidated financial information for the Company for the periods indicated.

(\$000s, except per share data)	12 Weeks Ended	
	March 26, 2011 (unaudited)	March 27, 2010 ⁽¹⁾ (unaudited)
Sales	\$ 2,347,021	\$ 2,284,433
Cost of goods sold	1,459,906	1,426,582
Gross profit	887,115	857,851
Operating and administrative expenses	709,223	669,951
Operating income	177,892	187,900
Finance expenses	14,641	13,877
Earnings before income taxes	163,251	174,023
Income taxes	45,710	51,771
Net earnings	\$ 117,541	\$ 122,252
Net earnings per common share		
- Basic	\$ 0.54	\$ 0.56
- Diluted	\$ 0.54	\$ 0.56
EBITDA ⁽²⁾	\$ 246,916	\$ 240,314

⁽¹⁾ In preparing its 2010 comparative information, the Company has adjusted amounts reported previously in financial statements prepared in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP"). (See Note 13 to the accompanying unaudited consolidated financial statements of the Company.)

⁽²⁾ Earnings before finance expenses, income taxes and depreciation and amortization. (See note 8 to the accompanying unaudited consolidated financial statements of the Company.)

Sales

Sales represent the combination of sales of the retail drug stores owned by the Associates, sales at Murale™ and sales of the home health care business, Shoppers Drug Mart Specialty Health Network Inc. and MediSystem Technologies Inc. The majority of the Company's sales are generated from its retail drug store network and the majority of the Company's assets are used in the operations of these stores. As such, the Company presents one operating segment in its consolidated financial statement disclosures. Sales at Murale™ and sales of the home health care business are included with front store sales of the Company's retail drug stores. Sales of Shoppers Drug Mart Specialty Health Network Inc. and MediSystem Technologies Inc. are included with prescription sales of the Company's retail drug stores.

Sales are recognized as revenue when the goods are sold to the customer. Revenue is net of returns and award credits. Where a sales transaction includes points awarded under the Shoppers Optimum® loyalty card program (the "Program"), revenue allocated to the Program points is deferred based on the fair value of the award credits and recognized as revenue when the Program points are redeemed and the Company fulfills its obligations to supply the awards.

Revenue is measured at the fair value of the consideration received or receivable from the customer for products sold or services supplied. However, for certain products or services, such as the sale of lottery tickets, third-party prepaid phone cards, third-party gift cards, postal products and services and public transportation tickets, the Company acts as an agent and, consequently, records only the amount of commission income in its sales.

Sales in the first quarter of 2011 were \$2.347 billion compared to \$2.284 billion in the same quarter last year, an increase of \$63 million or 2.7%, driven by strong front store growth in all regions of the country. On a same-store basis, sales increased 2.0% during the first quarter of 2011.

Prescription sales were \$1.150 billion in the first quarter of 2011 compared to \$1.155 billion in the first quarter of 2010, a decrease of \$5 million or 0.4%. During the first quarter of 2011, prescription sales accounted for 49.0% of the Company's sales mix compared to 50.6% in the same period last year. On a same-store basis, prescription sales also decreased 0.4% during the first quarter of 2011, as continued growth in the number of prescriptions filled was offset by a reduction in average prescription value. The decrease in average prescription value can be largely attributed to a reduction in generic prescription reimbursement rates, the result of recently implemented drug system reform initiatives in certain jurisdictions of Canada, principally Ontario, British Columbia, Alberta and Québec, combined with increasing generic prescription utilization rates. During the first quarter of 2011, total prescription counts increased 3.9% when compared to the same period last year and were up 3.7% on a same-store basis. In the first quarter of 2011, generic molecules represented 56.6% of prescriptions dispensed compared to 53.2% of prescriptions dispensed in the first quarter of 2010.

Front store sales were \$1.197 billion in the first quarter of 2011 compared to \$1.129 billion in the first quarter of 2010, an increase of \$68 million or 6.0%, as the Company continued to experience sales growth and market share gains in its core health, beauty and convenience categories. The Company's store network development program, which resulted in a year-over-year increase in selling space of 4.9%, continues to have a positive impact on sales growth, particularly in the front of the store. Front store sales growth was also aided by effective marketing campaigns, differentiated and impactful promotions and solid program execution at store level. On a same-store basis, front store sales increased 4.4% during the first quarter of 2011.

Cost of Goods Sold

Cost of goods sold is comprised of the cost of goods sold at the retail drug stores owned by the Associates, the cost of goods sold at Murale™ and the cost of goods sold at the home health care business, Shoppers Drug Mart Specialty Health Network Inc. and MediSystem Technologies Inc.

Cost of goods sold was \$1.460 billion in the first quarter of 2011 compared to \$1.427 billion in the same period last year, an increase of \$33 million or 2.3%. Expressed as a percentage of sales, cost of goods sold declined by 25 basis points in the first quarter of 2011 versus the same period last year, reflecting the benefits of improved purchasing synergies, partially offset by continued investments in pricing and promotional activities.

Operating and administrative expenses

Operating and administrative expenses include corporate selling, general and administrative expenses, operating expenses at the retail drug stores owned by the Associates, including Associates' earnings, operating expenses at Murale™ and operating expenses at the home health care business, Shoppers Drug Mart Specialty Health Network Inc. and MediSystem Technologies Inc. Operating and administrative expenses also include depreciation and amortization expenses. (See note 8 to the accompanying unaudited consolidated financial statements of the Company.)

Operating and administrative expenses, excluding depreciation and amortization expense, were \$640 million in the first quarter of 2011 compared to \$618 million in the same period last year, an increase of \$22 million or 3.7%. This increase can be largely attributed to higher expenses at store-level, primarily occupancy, Associate earnings, wages and benefits tied to the Company's network growth and expansion initiatives, partially offset by a reduction in corporate expenses and by further gains in productivity and efficiency at identical stores. Marketing expenses were also higher in the first quarter of 2011. Expressed as a percentage of sales, operating and administrative expenses, excluding depreciation and amortization expense, increased by 25 basis points in the first quarter of 2011 versus the comparative prior year period, an increase that also reflects, in part, the impact of top-line deflation stemming from the above referenced drug system reform initiatives and greater generic prescription utilization.

Depreciation and amortization expense was \$69 million in the first quarter of 2011 compared to \$52 million in the same period last year, with last year's amount inclusive of a \$12 million (pre-tax) gain in respect of a sale-leaseback transaction involving certain of the Company's retail properties. Excluding the impact of this gain from the comparative prior year period, the Company's depreciation and amortization expense increased by \$5 million or 7.1% during the first quarter of 2011. Expressed as a percentage of sales, depreciation and amortization expense increased by 12 basis points in the first quarter of 2011 when compared to the adjusted depreciation and amortization expense in the same period of last year, an increase which can be attributed to continued investments in the store network and supporting infrastructure.

Operating Income

Operating income was \$178 million in the first quarter of 2011 compared to \$188 million in the same period last year. Excluding the impact of last year's \$12 million (pre-tax) gain in respect of the sale-leaseback transaction referred to above, operating income increased by \$2 million or 1.2% in the first quarter of 2011. As described above, this result was driven by strong performance in the front of the store, improved purchasing synergies and further gains in productivity and efficiency, offset by the negative impact of drug system reform initiatives implemented in the second half of 2010 and higher operating costs associated with the Company's strategic growth and expansion initiatives, along with continued investments in marketing and promotional activities. Excluding the impact of the aforementioned sale-leaseback transaction from the prior year's results, first quarter operating margin (operating income divided by sales) declined by 12 basis points to 7.58% compared to an adjusted operating margin of 7.70% in the first quarter of 2010. The Company's EBITDA margin (EBITDA divided by sales), was 10.52% in the first quarter of 2011, unchanged when compared to the same period of the prior year.

Finance expenses

Finance expenses are comprised of interest expense arising from borrowings at the Associate-owned stores and from debt obligations of the Company, interest associated with financing leases and the amortization of transaction costs incurred in conjunction with debt transactions.

Finance expenses were \$15 million in the first quarter of 2011 compared to \$14 million in the same period last year, an increase of \$1 million or 5.5%. Interest expense was higher as a result of a market-driven increase in short-term interest rates on the Company's floating rate debt obligations, along with higher bank fees associated with the Company's revolving term credit facility which was refinanced in the fourth quarter of 2010. This higher interest expense was partially offset by interest expense savings due to the Company having a lower average amount of consolidated net debt outstanding during the quarter and from the maturity, in the fourth quarter of 2010, of an interest rate derivative agreement that converted an aggregate notional principal amount of \$50 million of floating rate debt into fixed rate debt.

Income Taxes

The Company's effective income tax rate in the first quarter of 2011 was 28.0% compared to a rate of 29.7% in the same period last year. This decrease in the effective income tax rate can be attributed to a reduction in statutory rates.

Net Earnings

First quarter net earnings were \$118 million compared to \$122 million in the same period last year. Excluding the impact of the aforementioned \$12 million (pre-tax) gain in respect of the sale-leaseback transaction from the prior year's results, the Company's net earnings increased by \$4 million or 3.3% during the first quarter of 2011. On a diluted basis, earnings per share were \$0.54 in the first quarter of 2011 compared to adjusted earnings per share of \$0.52 in the same period last year.

Capitalization and Financial Position

The following table provides a summary of certain information with respect to the Company's capitalization and consolidated financial position at the dates indicated.

(\$000s)	March 26, 2011	January 1, 2011 ⁽¹⁾
Cash	\$ (69,744)	\$ (64,354)
Bank indebtedness	223,832	209,013
Commercial paper	106,907	127,828
Current portion of long-term debt	249,459	-
Long-term debt	694,521	943,412
Net debt	1,204,975	1,215,899
Shareholders' equity	4,154,876	4,092,547
Total capitalization	\$ 5,359,851	\$ 5,308,446
Net debt:Shareholders' equity	0.29:1	0.30:1
Net debt:Total capitalization	0.22:1	0.23:1
Net debt:EBITDA ⁽²⁾	1.02:1	1.03:1
EBITDA:Cash interest expense ⁽²⁾⁽³⁾	19.87:1	20.06:1

⁽¹⁾ In preparing its 2010 comparative information, the Company has adjusted amounts reported previously in financial statements prepared in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP"). (See Note 13 to the accompanying unaudited consolidated financial statements of the Company.)

⁽²⁾ For purposes of calculating the ratios, EBITDA is comprised of the EBITDA for each of the 52 week periods then ended.

⁽³⁾ Cash interest expense is comprised of finance expenses for each of the 52 week periods then ended and excludes interest associated with financing leases and the amortization of deferred financing costs, but includes capitalized interest.

Financial Ratios and Credit Ratings

The following table provides a summary of the Company's credit ratings at March 26, 2011.

	Standard & Poor's	DBRS Limited
Corporate credit rating	BBB+	-
Senior unsecured debt	BBB+	A (low)
Commercial paper	-	R-1 (low)

There were no changes to any of the Company's credit ratings during the first quarter of 2011.

Outstanding Share Capital

The Company's outstanding share capital is comprised of common shares. An unlimited number of common shares is authorized and the Company had 217,473,716 common shares outstanding at April 25, 2011. As at this same date, the Company had issued options to acquire 933,117 of its common shares pursuant to its stock-based compensation plans, of which 811,031 were exercisable.

Normal Course Issuer Bid

On February 10, 2011, the Company's Board of Directors authorized the purchase of up to 8,700,000 of its common shares, representing approximately 4.0% of its common shares then outstanding, by way of normal course purchases effected through the facilities of the Toronto Stock Exchange (the "TSX"). The Company was able to commence purchases under this program on February 15, 2011. The program will terminate on February 14, 2012, or on such earlier date as the Company may complete its purchases pursuant to a Notice of Intention filed with the TSX. Purchases will be made by the Company in accordance with the requirements of the TSX and the price which the Company will pay for any such common shares will be the market price of any such common shares at the time of acquisition, or such other price as may be permitted by the TSX. For purposes of the TSX rules, a maximum of 170,759 common shares may be purchased by the Company on any one day under the bid, except where purchases are made in accordance with the "block purchase exception" of the TSX rules. Common shares purchased by the Company will be cancelled. As at April 25, 2011, no purchases had been made under this program.

Liquidity and Capital Resources

Sources of Liquidity

The Company has the following sources of liquidity: (i) cash provided by operating activities; (ii) cash available from a committed \$750 million revolving bank credit facility maturing December 10, 2014, less what is currently drawn and/or being utilized to support commercial paper issued and outstanding; and (iii) up to \$500 million in availability under its commercial paper program, less what is currently issued. The Company's commercial paper program is rated R-1 (low) by DBRS Limited. In the event that the Company's commercial paper program is unable to maintain this rating, the program is supported by the Company's \$750 million revolving bank credit facility. At March 26, 2011, \$10 million of the Company's \$750 million revolving bank credit facility was utilized, all in respect of outstanding letters of credit. At January 1, 2011, \$9 million of this facility was utilized, all in respect of outstanding letters of credit. At March 26, 2011, the Company had \$107 million of commercial paper issued and outstanding under its commercial paper program compared to \$128 million at the end of 2010.

The Company has also arranged for its Associates to obtain financing to facilitate their inventory purchases and fund their working capital requirements by providing guarantees to various Canadian chartered banks that support Associate loans. At the end of the first quarter of 2011, the Company's maximum obligation in respect of such guarantees was \$520 million, unchanged from the end of the prior year. At March 26, 2011, an aggregate amount of \$443 million in available lines of credit had been allocated to the Associates by the various banks compared to \$440 million at the end of the prior year. At March 26, 2011, Associates had drawn an aggregate amount of \$221 million against these available lines of credit compared to \$176 million at the end of the prior year. Any amounts drawn by the Associates are included in bank indebtedness on the Company's consolidated balance sheets. As recourse in the event that any payments are made under the guarantees, the Company holds a first-ranking security interest on all assets of Associate-owned stores, subject to certain prior-ranking statutory claims. As the Company is involved in allocating the available lines of credit to its Associates, it estimates that the net proceeds from secured assets would exceed the amount of any payments required in respect of the guarantees.

The Company has obtained additional long-term financing from the issuance of \$450 million of five-year medium-term notes maturing June 3, 2013, which bear interest at a fixed rate of 4.99% per annum (the "Series 2 Notes"), \$250 million of three-year medium-term notes maturing January 20, 2012, which bear interest at a fixed rate of 4.80% per annum (the "Series 3 Notes") and \$250 million of five-year medium-term notes maturing January 20, 2014, which bear interest at a fixed rate of 5.19% per annum (the "Series 4 Notes"). The Series 2 Notes were issued pursuant to a final short form base shelf prospectus dated May 22, 2008 (the "Prospectus"), as supplemented by a pricing supplement dated May 28, 2008. The Series 3 Notes and Series 4 Notes were issued pursuant to the Prospectus, as supplemented by pricing supplements dated January 14, 2009. The pricing supplements were filed by the Company with Canadian securities regulators in all of the provinces of Canada. At the time of issuance, the medium-term notes were assigned ratings of A (low) from DBRS Limited and BBB+ from Standard & Poor's.

Cash Flows From Operating Activities

Cash flows from operating activities were \$143 million in the first quarter of 2011, compared to \$148 million in the first quarter of the prior year. This decrease is largely the result of a reduction in net earnings, adjusted for non-cash items, as an increase in the amount invested in non-cash working capital balances was essentially offset by a reduction in income taxes paid.

Cash Flows Used in Investing Activities

Cash flows used in investing activities were \$75 million in the first quarter of 2011 compared to \$63 million in the same period last year, an increase of \$12 million or 19.4%. Of these totals, purchases of property and equipment, net of proceeds from any dispositions, amounted to \$59 million in the first quarter of 2011 compared to \$41 million in the same period last year. Included in the net purchases of property and equipment in the first quarter of 2010 was \$36 million of proceeds resulting from dispositions, \$35 million of which related to a sale/leaseback transaction involving 13 retail locations. The Company invested an additional \$6 million in business acquisitions and a combined \$10 million in the purchase and development of intangible and other assets during the first quarter of 2011 compared to \$11 million and \$11 million, respectively, in the same period last year. Investments in business acquisitions relate primarily to acquisitions of drug stores and prescription files, and while the Company will continue to pursue attractive opportunities in the marketplace, the pace of this activity has slowed somewhat in response to drug system reform initiatives implemented in a number of provincial jurisdictions.

During the first quarter of 2011, the Company opened or acquired 18 new drug stores, 11 of which were relocations, consolidated or closed 3 smaller drug stores and completed 4 major drug store expansions. In addition to this activity, 12 existing drug stores were remodeled, converting them to smaller prototype formats. At the end of the first quarter of 2011, there were 1,316 retail stores in the Company's network, comprised of 1,245 drug stores (1,185 Shoppers Drug Mart®/Pharmaprix® stores and 60 Shoppers Simply Pharmacy®/Pharmaprix Simplement Santé® stores), 63 Shoppers Home Health Care® stores and eight Murale™ stores.

Cash Flows Used in Financing Activities

Cash flows used in financing activities were \$62 million in the first quarter of 2011, as cash outflows of \$78 million were partially offset by cash inflows of \$16 million. Cash outflows were comprised of a \$21 million decrease in the amount of commercial paper issued and outstanding by the Company under its commercial paper program, a \$1 million repayment of financing lease obligations, a \$7 million reduction in the amount of Associate investment and \$49 million for the payment of dividends. Cash inflows were comprised of a \$15 million increase in bank indebtedness and \$1 million of proceeds received from the issuance of common shares and loan repayments under the Company's stock-based incentive plans.

In the first quarter of 2011, the net result of the Company's operating, investing and financing activities was an increase in cash balances of \$5 million.

Future Liquidity

The Company believes that its current credit facilities, commercial paper program and financing programs available to its Associates, together with cash generated from operating activities, will be sufficient to fund its operations, including the operations of its Associate-owned store network, investing activities and commitments for the foreseeable future. Historically, the Company has not experienced any major difficulty in obtaining additional short or long-term financing given its investment grade credit ratings. While the Company is committed to maintaining its investment grade credit ratings, credit ratings may be revised or withdrawn at any time by the rating agencies if, in their judgment, circumstances warrant.

NEW ACCOUNTING PRONOUNCEMENTS

Transition to International Financial Reporting Standards

The Company has adopted International Financial Reporting Standards (“IFRS”) for its 2011 fiscal year as required by the Accounting Standards Board of the Canadian Institute of Chartered Accountants. The Company provided information on its transition to IFRS in its 2010 Annual Management’s Discussion and Analysis. The assessments and impacts discussion in the 2010 Annual Management’s Discussion and Analysis remain largely unchanged.

The Company has completed its assessment of lease classifications. For certain leases, this assessment resulted in the recognition of financing leases under IFRS where previously, they had been considered operating leases under Canadian GAAP. Upon implementation of IFRS, the Company recognized an increase in property and equipment of \$51.2 million, an increase in accounts payable and accrued liabilities of \$1.2 million, an increase in other long-term liabilities of \$53.3 million, a decrease in deferred tax liabilities of \$1.5 million and an associated after-tax charge to retained earnings of \$1.8 million. Prior to adopting IFRS, the Company recognized a future tax asset on the temporary difference between the cost base and the tax base of inventory. This temporary difference relates primarily to consideration received from vendors which is classified as a reduction to the cost of inventory on consolidation. Under IFRS, this reduction to the cost of inventory is not considered a temporary difference and, as such, there is no deferred tax asset. Upon implementation of IFRS, the Company recognized a decrease in deferred tax assets of \$60.7 million and a corresponding decrease in retained earnings.

The Company has provided a detailed explanation of the impacts of this transition in Note 13 of the Company’s first quarter 2011 unaudited interim period financial statements (“Note 13”). Note 13 includes reconciliations of the Company’s balance sheet and shareholders’ equity from Canadian GAAP to IFRS as at January 1, 2011, March 27, 2010 and January 3, 2010, and its fiscal 2010 net earnings and comprehensive income for the 52 weeks ended January 1, 2011 and 12 weeks ended March 27, 2010. Explanations of the individual impacts of adopting IFRS identified in the reconciliations are also provided, as are the Company’s elections under IFRS 1 “First-time Adoption of International Financial Reporting Standards”.

Future Accounting Standards

Financial Instruments – Disclosures

The International Accounting Standards Board (the “IASB”) has issued an amendment to IFRS 7, “Financial Instruments: Disclosures” (the “IFRS 7 amendment”), requiring incremental disclosures regarding transfers of financial assets. The IAS 7 amendment is effective for annual periods beginning on or after July 1, 2011. The Company will apply the amendment at the beginning of its 2012 financial year and does not expect the implementation to have a significant impact on the Company’s disclosures.

Deferred Taxes – Recovery of Underlying Assets

The IASB has issued an amendment to IAS 12, “Income Taxes” (the “IAS 12 amendment”), that introduces an exception to the general measurement requirements of IAS 12 in respect of investment properties measured at fair value. The IAS 12 amendment is effective for annual periods beginning on or after January 1, 2012. The Company will apply the amendment at the beginning of its 2012 financial year. The Company has yet to assess the impact of the IAS 12 amendment on its results of operations, financial position and disclosures.

Financial Instruments

The IASB has issued a new standard, IFRS 9, “Financial Instruments” (“IFRS 9”), which will ultimately replace IAS 39, “Financial Instruments: Recognition and Measurement” (“IAS 39”). The replacement of IAS 39 is a multi-phase project with the objective of improving and simplifying the reporting for financial instruments and the issuance of IFRS 9 is part of the first phase of this project. This standard becomes effective on January 1, 2013. The Company has yet to assess the impact of the new standard on its results of operations, financial position and disclosures.

SELECTED QUARTERLY INFORMATION

Reporting Cycle

The annual reporting cycle of the Company is divided into four quarters of 12 weeks each, except for the third quarter which is 16 weeks in duration. The fiscal year of the Company consists of a 52 or 53 week period ending on the Saturday closest to December 31. When a fiscal year consists of 53 weeks, the fourth quarter is 13 weeks in duration.

Summary of Quarterly Results

The following table provides a summary of certain selected consolidated financial information for the Company for each of the eight most recently completed fiscal quarters. Except where noted, this information has been prepared in accordance with IFRS.

	First Quarter		Fourth Quarter		Third Quarter		Second Quarter	
(\$000s, except per share data – unaudited)	2011 (12 Weeks)	2010 (12 Weeks)	2010 (12 Weeks)	2009 ⁽¹⁾ (12 Weeks)	2010 (16 Weeks)	2009 ⁽¹⁾ (16 Weeks)	2010 (12 Weeks)	2009 ⁽¹⁾ (12 Weeks)
Sales	\$ 2,347,021	\$ 2,284,433	\$ 2,499,965	\$ 2,488,544	\$ 3,047,430	\$ 3,013,007	\$ 2,360,887	\$ 2,288,789
Net earnings	\$ 117,541	\$ 122,252	\$ 168,906	\$ 171,060	\$ 154,724	\$ 170,894	\$ 145,970	\$ 136,112
Per common share								
- Basic net earnings	\$ 0.54	\$ 0.56	\$ 0.78	\$ 0.79	\$ 0.71	\$ 0.79	\$ 0.67	\$ 0.63
- Diluted net earnings	\$ 0.54	\$ 0.56	\$ 0.78	\$ 0.79	\$ 0.71	\$ 0.79	\$ 0.67	\$ 0.63

⁽¹⁾ The selected information that is presented for quarterly periods in fiscal 2009 does not reflect the impact of the adoption of International Financial Reporting Standards (“IFRS”).

The Company experienced growth in sales in each of the four most recent quarters when compared to the same quarters of the prior year.

Net earnings increased in the second quarter of 2010 when compared to the same quarter of the prior year. Although not directly comparable, net earnings decreased in the third quarter of 2010 when compared to the same quarter of the prior year due in part to the impact of the drug system reform initiatives implemented in certain jurisdictions of Canada, principally Ontario, which negatively impacted pharmacy reimbursement and margin rates, and also due to a charge of \$10 million (pre-tax) to settle a long-standing legal dispute related to a commercial arrangement with one of the Company’s ancillary businesses. While also not directly comparable, net earnings decreased in the fourth quarter of 2010 and the first quarter of 2011 when compared to the same quarter of the prior year, partly the result of downward pressure on sales and margins in the dispensary, partially offset by strong performance in the front of the store, improved purchasing synergies and continued gains in productivity and efficiency, but also due to the recognition of certain non-recurring items as a result of the adoption of IFRS. (See Note 13 to the accompanying unaudited consolidated financial statements of the Company.)

The Company’s core prescription drug operations are not typically subject to seasonal fluctuations. The Company’s front store operations include seasonal promotions which may have an impact on comparative quarterly results, particularly when a season, notably Easter, does not fall in the same quarter each year. Also, as the Company continues to expand its front store product and service offerings, including seasonal promotions, its results of operations may become subject to more seasonal fluctuations.

RISKS AND RISK MANAGEMENT

Industry and Regulatory Developments

The Company is exposed to a number of risks in the normal course of its business that have the potential to affect its operating and financial performance, including the risk of adverse drug system reform initiatives which may adversely impact the revenues and profitability that may be derived from prescription drug sales. The Company is reliant on prescription drug sales for a significant portion of its sales and profits.

The following is a discussion of significant industry and regulatory developments since the date of the Company's Annual Management's Discussion and Analysis for the 52 week period ended January 1, 2011:

Nova Scotia

On April 11, 2011, the Nova Scotia Minister of Health and Wellness introduced Bill No. 17, the Fair Drug Pricing Act ("Bill 17"), for first reading in the Nova Scotia legislature. Bill 17, when passed, is intended to create a stand-alone act to oversee the public drug plans in the province which will allow the government to regulate the cost of generic drugs to enable lower drug pricing under its public drug plans. Bill 17 includes provisions that are intended to allow the government to regulate activities of providers of pharmacy services in relation to any matters under the legislation including the ability to impose rules, terms, restrictions or conditions respecting rebates and professional allowances.

The Nova Scotia government also announced its drug pricing plan for the province (the "NS Plan") on April 11, 2011. As specified in the NS Plan, a cap will be set on the price of all generic drugs, both new and existing, at a percentage of the price of the equivalent brand name drug. The cap will be phased in over a one year period as follows:

July 1, 2011 – generic drugs will be priced at 45 percent of the price of the equivalent brand name drug;

January 1, 2012 – generic drugs will be priced at 40 percent of the price of the equivalent brand name drug; and

July 1, 2012 – generic drugs will be priced at 35 percent of the price of the equivalent brand name drug.

Rules will also be put in place to limit increases in the price of generic drugs.

The Nova Scotia government announced that it will continue to work with pharmacies to move to reimbursing at a more clearly defined price. The Nova Scotia government also indicated in the announcement that, while Bill 17 includes provisions that will allow use of such measures, at this time it will not tender for drugs or limit or require reporting of rebates in the province.

Finally, the Nova Scotia government indicated in the announcement that it has established a Drug Management Policy Unit which will focus on better use of drugs and effectively managing drug costs.

It is anticipated that Bill 17 and the regulations to support the NS Plan will be finalized in June and go into effect on July 1, 2011.

Where legislative or other measures that appear to be effective in reducing prescription drug costs are implemented in one jurisdiction, governments in other provincial jurisdictions are looking or may look to implement similar measures. In some provincial jurisdictions, elements of the laws and regulations that impact pharmacy reimbursement and manufacturer allowances for sales to the public drug plans may be extended by legislation to sales in the private sector. Also, private third-party payers (such as corporate employers and their insurers) are looking or may look to benefit from any measures implemented by government payers to reduce prescription drug costs for public plans by attempting to extend these measures to prescription drug plans they own or manage. Accordingly, changes to pharmacy reimbursement and manufacturer allowances for a public drug plan could also impact pharmacy reimbursement and manufacturer allowances for private sector sales. In addition, private third-party payers could reduce pharmacy reimbursement for prescription drugs provided to their members.

Changes impacting pharmacy reimbursement programs, prescription drug pricing and manufacturer allowance funding, legislative or otherwise, may have a material adverse impact on the Company's business, sales and profitability. In addition, the Company could incur significant costs in the course of complying with any changes in the regulatory regime affecting prescription drugs. Non-compliance with any such existing or proposed laws or regulations, particularly those that provide for the licensing and conduct of wholesalers, the licensing and conduct of pharmacists, the regulation and ownership of pharmacies, the advertising of pharmacies and prescription services, the provision of information concerning prescription drug products, the pricing of prescription drugs and restrictions on manufacturer allowance funding, could result in civil or regulatory proceedings, fines, penalties, injunctions, recalls or seizures, any of which may impact the Company's business, sales or profitability.

RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS

The Company is exposed to a number of risks associated with financial instruments that have the potential to affect its operating and financial performance. The Company's primary financial instrument risk exposures are interest rate risk and liquidity risk. The Company's exposures to foreign currency risk, credit risk and other price risk are not considered to be material. The Company may use derivative financial instruments to manage certain of these risks but it does not use derivative financial instruments for trading or speculative purposes.

Exposure to Interest Rate Fluctuations

The Company, including its Associate-owned store network, is exposed to fluctuations in interest rates by virtue of its borrowings under its bank credit facilities, commercial paper program and financing programs available to its Associates. Increases or decreases in interest rates will negatively or positively impact the financial performance of the Company.

The Company monitors market conditions and the impact of interest rate fluctuations on its fixed and floating rate debt instruments on an ongoing basis and may use interest rate derivatives to manage this exposure. Currently, the Company is not party to interest rate derivative agreements. In 2010, the Company used an interest rate derivative agreement to convert an aggregate notional principal amount of \$50 million of floating rate debt into fixed rate debt. The fixed rate payable by the Company under this agreement was 4.18% and contained reset terms of one month. This agreement matured in December 2010.

Furthermore, the Company may be exposed to losses should any counterparty to its derivative agreements fail to fulfill its obligations. The Company seeks to minimize counterparty risk by transacting with counterparties that are large financial institutions. There was no such exposure as at March 26, 2011, as the Company was not party to any interest rate derivative agreements as at that date.

As at March 26, 2011, the Company had \$328 million (2010 - \$459 million) of unhedged floating rate debt. During the 12 weeks ended March 26, 2011, the Company's average outstanding unhedged floating rate debt was \$480 million (2010 - \$618 million). Had interest rates been higher or lower by 50 basis points during the period, net earnings would have decreased or increased, respectively, by approximately \$0.4 million (2010 - \$0.5 million) as a result of the Company's exposure to interest rate fluctuations on its unhedged floating rate debt.

Foreign Currency Exchange Risk

The Company conducts the vast majority of its business in Canadian dollars. The Company's foreign currency exchange risk principally relates to purchases made in U.S. dollars and this risk is tied to fluctuations in the exchange rate of the Canadian dollar vis-à-vis the U.S. dollar. The Company monitors its foreign currency purchases in order to monitor and manage its foreign currency exchange risk. The Company does not consider its exposure to foreign currency exchange rate risk to be material.

Credit Risk

Accounts receivable arise primarily in respect of prescription sales billed to governments and third-party drug plans and, as a result, collection risk is low. There is no concentration of balances with debtors in the remaining accounts receivable. The Company does not consider its exposure to credit risk to be material.

Other Price Risk

The Company uses cash-settled equity forward agreements to limit its exposure to future changes in the market price of its common shares by virtue of its obligations under its long-term incentive plan ("LTIP") and restricted share unit plan ("RSU Plan"). The income or expense arising from the use of these instruments is included in operating and administrative expenses.

Based on market values of the equity forward agreements in place at March 26, 2011, the Company recognized a liability of \$1.5 million, of which \$0.4 million was presented in accounts payable and accrued liabilities and \$1.1 million was presented in other long-term liabilities. Based on market values of the equity forward agreements in place at March 27, 2010, the Company recognized a liability of \$2.1 million, of which \$1.4 million was presented in accounts payable and accrued liabilities and \$0.7 million was presented in other long-term liabilities. During the 12 week periods ended March 26, 2011 and March 27, 2010, the Company assessed that the percentages of the equity forward agreements in place related to unearned units under the LTIP and RSU Plan were effective hedges for its exposure to future changes in the market price of its common shares in respect of the unearned units. Market values were determined based on information received from the Company's counterparty to these equity forward agreements.

Capital Management and Liquidity Risk

The Company's primary objectives when managing its capital are to profitably grow its business while maintaining adequate financing flexibility to fund attractive new investment opportunities and other unanticipated requirements or opportunities that may arise. Profitable growth is defined as earnings growth commensurate with the additional capital being invested in the business in order that the Company earns an attractive rate of return on that capital. The primary investments undertaken by the Company to drive profitable growth include additions to the selling square footage of its store network via the construction of new, relocated and expanded stores, including related leasehold improvements and fixtures, the acquisition of sites as part of a land bank program, as well as through the acquisition of independent drug stores or their prescription files. In addition, the Company makes capital investments in information technology and its distribution capabilities to support an expanding store network. The Company also provides working capital to its Associates via loans and/or loan guarantees. The Company largely relies on its cash flow from operations to fund its capital investment program and dividend distributions to its shareholders. This cash flow is supplemented, when necessary, through the borrowing of additional debt. No changes were made to these objectives during the period.

The Company considers its total capitalization to be bank indebtedness, commercial paper, short-term debt, long-term debt (including the current portion thereof) and shareholders' equity, net of cash. The Company also gives consideration to its obligations under operating and financing leases when assessing its total capitalization. The Company manages its capital structure with a view to maintaining investment grade credit ratings from two credit rating agencies. In order to maintain its desired capital structure, the Company may adjust the level of dividends paid to shareholders, issue additional equity, repurchase shares for cancellation or issue or repay indebtedness. The Company has certain debt covenants and is in compliance with those covenants.

The Company monitors its capital structure principally through measuring its net debt to shareholders' equity ratio and net debt to total capitalization ratio, and ensures its ability to service its debt and meet other fixed obligations by tracking its interest and other fixed charges coverage ratios. (See discussion under "Capitalization and Financial Position" in this Management's Discussion and Analysis.)

Liquidity risk is the risk that the Company will be unable to meet its obligations relating to its financial liabilities. The Company prepares cash flow budgets and forecasts to ensure that it has sufficient funds through operations, access to bank credit facilities and access to debt and capital markets to meet its financial obligations, capital investment program and fund new investment opportunities or other unanticipated requirements as they arise. The Company manages its liquidity risk as it relates to financial liabilities by monitoring its cash flow from operating activities to meet its short-term financial liability obligations and planning for the repayment of its long-term financial liability obligations through cash flow from operating activities and/or the issuance of new debt.

For a complete description of the Company's sources of liquidity, see the discussions under "Sources of Liquidity" and "Future Liquidity" under "Liquidity and Capital Resources" in this Management's Discussion and Analysis.

INTERNAL CONTROL OVER FINANCIAL REPORTING

The Chief Executive Officer and the Chief Financial Officer have designed, or caused to be designed under their supervision, internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Canadian GAAP. Internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be designed effectively can provide only reasonable assurance with respect to financial reporting and financial statement preparation.

There were no changes in internal control over financial reporting that occurred during the Company's most recent interim period that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

NON-IFRS FINANCIAL MEASURES

The Company reports its financial results in accordance with IFRS. However, the foregoing contains references to non-IFRS financial measures, such as adjusted depreciation and amortization, operating margin, EBITDA (earnings before finance expenses, income taxes and depreciation and amortization), EBITDA margin, adjusted earnings, adjusted earnings per share and cash interest expense. Non-IFRS financial measures do not have standardized meanings prescribed by IFRS and, therefore, may not be comparable to similar measures presented by other reporting issuers.

These non-IFRS financial measures have been included in this Management's Discussion and Analysis as they are measures which management uses to assist in evaluating the Company's operating performance against its expectations and against other companies in the retail drug store industry. Management believes that non-IFRS financial measures assist in identifying underlying operating trends.

These non-IFRS financial measures, particularly EBITDA and EBITDA margin, are also common measures used by investors, financial analysts and rating agencies. These groups may use EBITDA, EBITDA margin and other non-IFRS financial measures to value the Company and assess the Company's ability to service its debt.